MedTrace Logo

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study

NCT05860400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2025-11-19

No results posted yet for this study

Summary

This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.

Conditions

Interventions

BEHAVIORAL

Healthy life style

Healthy diet, regular exercise, and quitting smoking

DRUG

Secondary prevention for atherosclerotic coronary artery disease

Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose

DRUG

Immunosuppressive therapy

Glucocorticoids and/or immunosuppressive agents

PROCEDURE

Coronary revascularization

Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG).

DRUG

Supportive therapies

Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Zhenyu Liu, M.D. · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-17
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05860400 on ClinicalTrials.gov